Overview of Clinical and Research Activities at Georgetown University Hospital

Similar documents
Radiotherapy physics & Equipments

Therapeutic Medical Physics. Stephen J. Amadon Jr., Ph.D., DABR

EORTC Member Facility Questionnaire

PHYS 383: Applications of physics in medicine (offered at the University of Waterloo from Jan 2015)

Advances in external beam radiotherapy

ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER

NIA MAGELLAN HEALTH RADIATION ONCOLOGY CODING STANDARD. Dosimetry Planning

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

I. Equipments for external beam radiotherapy

Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?

Has radiotherapy the potential being focal?

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the

Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy

Radiation Therapy 2013 The Role of Protons. Bob Gaston, D.O.

Brachytherapy an Overview

Beam Direction RAO LAO. Pt supine. LL Treatment couch LPO RPO. WHA Consulting. Wilson Apollo

Hampton University Proton Therapy Institute

MEDICAL MANAGEMENT POLICY

An introduction to different types of radiotherapy

Palliative RT in Ovarian cancer

Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?

Changing Paradigms in Radiotherapy

PROGRESS IN RADIATION ONCOLOGY. Fox Chase Cancer Center. Jean Holland RN MSN AOCN Department of Radiation Oncology April 2017

Cell survival following high dose rate flattening filter free (FFF) and conventional dose rate irradiation

Sample UC Irvine Medical Dosimetry Program Official Transcript

Jean Pouliot, PhD Professor and Vice Chair, Department of Radiation Oncology, Director of Physics Division

Review of brachytherapy in

Rob Glynne-Jones Mount Vernon Cancer Centre

Peak temperature ratio of TLD glow curves to investigate the spatial variation of LET in a clinical proton beam

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

Varian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

Questions may be submitted anytime during the presentation.

Image Guided Proton Therapy and Treatment Adaptation

ACR TXIT TM EXAM OUTLINE

First, how does radiation work?

External Beam Radiotherapy for Prostate Cancer

Implementation of advanced RT Techniques

Assistant Professor Department of Therapeutic Radiology Yale University School of Medicine

OPPORTUNITIES IN BRACHYTHERAPY

Imaging of Scattered Radiation for Real Time Tracking of Tumor Motion During Lung SBRT

PRINCIPLES and PRACTICE of RADIATION ONCOLOGY. Matthew B. Podgorsak, PhD, FAAPM Department of Radiation Oncology

The TomoTherapy System as a Tool of Differentiation in Quality and Marketability

From position verification and correction to adaptive RT Adaptive RT and dose accumulation

Understanding Radiation Therapy. For Patients and the Public

RADIATION THERAPY PROCEDURES REQUIRING PRECERTIFICATION FOR EVICORE HEALTHCARE ARRANGEMENT

What is radiation quality?

Nuclear Data for Radiation Therapy

Y90 SIRT Therapy Dosimetric Aspects

IMRT - Intensity Modulated Radiotherapy

Brachytherapy Planning and Quality Assurance w Classical implant systems and modern computerized dosimetry w Most common clinical applications w

Radiobiological principles of brachytherapy

Cervical Cancer Treatment

Brachytherapy Planning and Quality Assurance

Efficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO

Ion Beam Therapy should we prioritise research on helium beams?

Radiation qualities in carbon-ion radiotherapy at NIRS/HIMAC

Assessing Heterogeneity Correction Algorithms Using the Radiological Physics Center Anthropomorphic Thorax Phantom

Nuclear Medicine and PET. D. J. McMahon rev cewood

Implementing New Technologies for Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

SunCHECK Patient Comprehensive Patient QA

Prostate Cancer Treatment

Stereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS

PGY-1. Resident Review Session Schedule

Out-of-field doses of CyberKnife in stereotactic radiotherapy of prostate cancer patients

HDR vs. LDR Is One Better Than The Other?

Radiotherapy Advances

It s All About Margins. Maaike Milder, Ph.D. Accuray Symposium April 21 st 2018

SCOPE OF ACCREDITATION TO ISO/IEC 17025:2005 & ANSI/NCSL Z

The objective of this lecture is to integrate our knowledge of the differences between 2D and 3D planning and apply the same to various clinical

Who Should Know Radiation Oncology Coding?

Improving clinical brachytherapy: dosimetry & verification

Chapter 5 Section 3.1

New Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital

Proton and heavy ion radiotherapy: Effect of LET

Introduction. Modalities used in imaging guidance. Flat panel detector. X-ray Imaging Dose to Patients in the Era of Image-Guided Radiation Therapy

La ricerca e la terapia in adroterapia-2. R.Orecchia / P. Fossati

How ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery

LET, RBE and Damage to DNA

Post-Lumpectomy Radiation Techniques and Toxicities

Beyond the DVH: Voxelbased Automated Planning and Quality Assurance

Design of a BSA for Producing Epithermal Neutron for BNCT

Sordina IORT Technologies S.p.A. Liac The mobile electron accelerator that revolutionizes IORT

Brachytherapy. What is brachytherapy and how is it used?

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Intensity Modulated RadioTherapy

The Physics of Oesophageal Cancer Radiotherapy

Isoeffective Dose Specification of Normal Liver in Yttrium-90 Microsphere Radioembolization*

Partial Breast Irradiation using adaptive MRgRT

Physical Bases : Which Isotopes?

Overview of Advanced Techniques in Radiation Therapy

Neutron dose evaluation in radiotherapy

Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy

Current Status of Electronic Brachytherapy Dosimetry

Cancer Treatment by Charged Particles - Carbon Ion Radiotherapy -

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

Transcription:

Overview of Clinical and Research Activities at Georgetown University Hospital Dalong Pang, Ph.D. Department of Radiation Medicine Georgetown University Hospital

Clinical Operation Two Varian linear accelerators Varian IX Varian Trilogy

3-D CRT IMRT VMAT Electron

Two Cyberknives

SRS, SBRT lung prostate Brain

One Gamma-Med HDR unit Mostly Gyn using vaginal cylinders

Prostate Seed Implant B&K ultrasound, Variseed planning, Pd-103, either Mono (125 Gy) or boost (76 Gy)

Cs-137 LDR Implant Ir-192 LDR Implant

Electronic Brachytherapy Carl Zeiss Intra-Beam System (IORT) Robotic arm applicators X-ray source

Intra-Beam RT Surgical removal of the tumor Applicator with X-ray probe positioned in the lumpectomy site. Treatment last for about 20 to 50minute to deliver 20Gy in single fraction to the applicator surface

Basic Characteristics A single fraction RT to lumpectomy wall X-ray energy: 50 kvp Dose: 20 Gy at cone surface and 7 Gy at 1-cm depth Treatment time (20-60 minutes) depends on cone size (1.5 cm to 6 cm)

SIR-Spheres Y-90 Resin Microspheres Use of Radioactive Y-90 resin spheres for the treatment of metastatic colorectal cancer in the liver.

Y-90: beta emitter, half life: 64 hours, mean energy: 0. 93 MeV, mean range: 2.5 mm. Intra-arterial delivery Amount of activity depends on patient size, weight, liver lobe volume and lesion volumes BSA 2 0.725 0.425 m 0.20247 ht m wt(kg)

Basic and Clinical Research 1. Atomic Force Microscopy (AFM) investigation of DNA fragmentation by high-let charged particles DNA is the critical cellular target of radiation; DNA DSBs are the most lethal DNA lesions. Higher LET leads to higher RBE- rationale for heavy charged particle therapy High-LET radiation induces complex DSB lesions that are more difficult to repair.

Method for Quantifying DSBs: AFM

Irradiation of DNA Molecules at Various Laboratories Georgetown: Electron AFRRI: Neutron Oak Ridge: Beryllium Chiba Japan: Argon

AFM Measurement of Irradiated DNA e - n 0 Be ++ Ar ++

DNA Fragment Size Distributions of Electron and Neutron Irradiated DNA e - n0 Be ++ Ar ++

Average DSB and DSB Spatial Distribution can be derived from the size distribution profiles. DSB clustering can be demonstrated <DSB>= n/n 0 Sparely: Low-LET Clustered: High-LET

Significance of Research 1. Direct visualization of individual DNA fragments 2. Experimental demonstration of clustered DNA DSB 3. Correlation of DNA clustering with LET of radiation 4. Data aid in theoretical modeling of DNA damage: Monte Carlo simulation, Microdosimetry 5. DNA damage repair

2. Circulating Cell-Free DNA: a Potential Biomarker for Cancer Diagnosis and Treatment Response? 1. Cancer Diagnosis 2. Treatment Response 3. Similar genetic or mutational information in DNAs extracted

Quantitative-PCR is the primary method for studies of cfdna: Concentration Mutation DNA fragment size index Cancer vs. no cancer Concentration is significantly greater in patients with cancer There is a difference in fragment size index Treatment response Successful treatment results in reduced concentration

Hypothesis: DNA fragment size distributions may reveal more information on tumor characteristics AFM used to measure DNA sizes

Our Focus: Radiation Treatment Response Blood samples collected from patients with pancreatic cancer, metastatic colorectal cancer, prostate cancer before and after treatments. blood spin Extraction of ccfdna and AFM imaging Measurement of fragment size distribution

Construction of a Nanofluidic device for rapid DNA size measurement (T. Kole, MD) In collaboration with NIST nanofabrication Lab Working on image process software for automatic fragment size measurement

4. Treatment Planning Automation: Knowledge-Based Optimization Continuation and expansion of OVH-driven treatment planning optimization (Binbin Wu, PhD) Application in Cyberknife Planning Application of IMRT database to VMAT planning Application in plan generation for different institutions

OVH-based optimization aid in Cyberknife planning A data base containing 500 cyberknife plans OVH calculated, PTV, OAR volumes compiled New plans generated retrospectively and prospectively Comparison to existing plans showed equal or better plan quality

Comparison of OVH Plans with Clinical Plans Mean dose to bladder reduces from 17.4Gy in CPs to 13.8Gy in APs 20.7% (3.6Gy) reduction Mean dose to rectum reduces from 16.8Gy in CPs to 14.8Gy in APs 12% (2Gy) reduction

Use of one institution s database to generate plans for another institution 1. H&N plans from a Dutch hospital: 45 patient H&N plans using 7 beam IMRT. SIB-IMRT, 68Gy and 50.3Gy. 2. New plan generated for each patient using JUH database 178 H&N SIB-IMRT plans with three-dose-level: 70Gy, 63Gy and 58.1Gy. 3. Comparison between the plans on DVH demonstrates comparable quality between the OVH-driven plans and the Dutch plans.

100 100 90 90 CP 80 PTV50.3 PTV68 80 AP 70 60 50 40 30 20 10 CP AP Cord 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 74 Dose (Gy) 100 90 80 70 Larynx CP AP 70 60 50 40 30 20 10 Brainstem Mandible 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 74 Dose (Gy) 100 90 80 70 AP CP 60 Oral cavity 60 50 40 30 50 40 30 I Parotid 20 10 20 10 C Parotid 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 74 Dose (Gy) 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 Dose (Gy)

New Development Construction for a Mevion S250 proton system underway

Treatment room Planar X-ray panels Mobile CT

Project Progress current December, 2016

Thank You!